Live news related to MEDINCELL stock (FR0004065605): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The biotech company from Montpellier falls sharply mid-morning, after leading the SBF 120 in the previous session. The stock sinks to the bottom of th…
The biotech company from Montpellier advances at the opening, going against the grain of a Parisian market weighed down by a resurgence of geopolitica…
The biotech company from Montpellier moves forward at midday, in stark contrast to a declining Parisian market. The stock climbs to the forefront of t…
The Montpellier-based biotech regains momentum mid-morning, following a sharp drop after the release of its annual financial statements. The stock is …
The biotech company from Montpellier opens the session with heavy penalties. The stock collapses as the annual results show a significant deepening of…
Medincell continues its pivot towards recurring revenue: royalties from its first commercialized product, Uzedy (risperidone), have surged by 42% to €…
The biotech company from Montpellier is moving forward on the eve of its annual financial report. The stock is among the top performers in the SBF 120…
The biotech company from Montpellier experiences a sharp decline mid-session, going against its recent momentum. The stock struggles at the bottom of …
The biotech company from Montpellier advances in mid-morning trading, bucking the trend of a Parisian market weighed down by inflationary fears linked…
The biotech company from Montpellier continues its recovery in late morning trading, in a Parisian market trending upwards. The stock benefits from ne…
